

Vivian Lui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/917972/publications.pdf>

Version: 2024-02-01

129
papers

7,095
citations

66234

42
h-index

62479

80
g-index

132
all docs

132
docs citations

132
times ranked

9590
citing authors

#	ARTICLE	IF	CITATIONS
1	Precision drugging of the MAPK pathway in head and neck cancer. <i>Npj Genomic Medicine</i> , 2022, 7, 20.	1.7	22
2	Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study. <i>EBioMedicine</i> , 2021, 65, 103242.	2.7	10
3	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF- κ B activation and immune escape. <i>Nature Communications</i> , 2021, 12, 4193.	5.8	56
4	Translational genomics of nasopharyngeal cancer. <i>Seminars in Cancer Biology</i> , 2020, 61, 84-100.	4.3	90
5	The Intersection between Oral Microbiota, Host Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3425.	1.7	33
6	Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 92.	18.1	1,649
7	Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 262.	3.5	13
8	Combinations of proteasome inhibitors with obatoclox are effective for small cell lung cancer. <i>Acta Pharmacologica Sinica</i> , 2020, 42, 1298-1310.	2.8	5
9	Microneedles loaded with anti-PD-1 cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. <i>Nanoscale</i> , 2020, 12, 18885-18898.	2.8	67
10	Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes. <i>Cancers</i> , 2020, 12, 2935.	1.7	4
11	Omics-wide quantitative B-cell infiltration analyses identify GPR18 for human cancer prognosis with superiority over CD20. <i>Communications Biology</i> , 2020, 3, 234.	2.0	13
12	Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey. <i>JCO Oncology Practice</i> , 2020, 16, e770-e778.	1.4	7
13	Emerging Roles of ALK in Immunity and Insights for Immunotherapy. <i>Cancers</i> , 2020, 12, 426.	1.7	12
14	Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma. <i>Npj Genomic Medicine</i> , 2020, 5, 17.	1.7	8
15	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. <i>Life Science Alliance</i> , 2020, 3, e201900545.	1.3	27
16	Germline mutation and aberrant transcripts of <i>WWOX</i> in a syndrome with multiple primary tumors. <i>Journal of Pathology</i> , 2019, 249, 19-25.	2.1	4
17	Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2019, 20, 52-64.	1.5	5
18	Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 221-232.	2.0	41

#	ARTICLE	IF	CITATIONS
19	Mesenchymal stem cells participate in oral mucosa carcinogenesis by regulating T cell proliferation. <i>Clinical Immunology</i> , 2019, 198, 46-53.	1.4	15
20	Effects of Salivary Mg on Head and Neck Carcinoma via TRPM7. <i>Journal of Dental Research</i> , 2019, 98, 304-312.	2.5	11
21	Abstract 4507: Study of CCCTC-binding factor (CTCF) genetic aberrations and dysregulation in head and neck squamous cell carcinoma (HNSCC). , 2019, , .		0
22	Abstract 4033: RAC1 genomic aberrations as predictive biomarkers for head and neck squamous cell carcinoma (HNSCC). , 2019, , .		1
23	Abstract 2527: Genomic aberrations of <i>ALK</i> in head and neck squamous cell carcinoma. <i>Cancer Research</i> , 2019, 79, 2527-2527.	0.4	1
24	Abstract 4933: RAPTOR protein overexpression is predictive of poor clinical outcomes in head and neck squamous cell carcinoma (HNSCC) patients. , 2019, , .		0
25	Abstract 98: Stromal-targeting with quercetin in patient-derived models of head and neck squamous cell carcinoma (HNSCC). , 2019, , .		0
26	Prediction of radiotherapy response with a 5 th microRNA signature-based nomogram in head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 726-735.	1.3	40
27	Hypermethylation of NF- κ B-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 676-686.	1.1	12
28	Thrombomodulin (TM) in tumor cell differentiation and periphery blood immune microenvironment in oral squamous cell carcinoma. <i>Clinical Immunology</i> , 2018, 191, 27-33.	1.4	5
29	Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein-Barr virus in situ assays. <i>Cancer</i> , 2018, 124, 434-435.	2.0	2
30	Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. <i>Oncology</i> , 2018, 7, e1388484.	2.1	23
31	The <i>RARS-MAD1L1</i> Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 659-673.	3.2	47
32	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 1107.	1.1	12
33	Microneedle-Mediated Delivery of Lipid-Coated Cisplatin Nanoparticles for Efficient and Safe Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 33060-33069.	4.0	125
34	Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer. <i>Cancers</i> , 2018, 10, 210.	1.7	43
35	Case Report: Exome sequencing reveals recurrent RETSAT mutations and a loss-of-function POLDIP2 mutation in a rare undifferentiated tongue sarcoma. <i>F1000Research</i> , 2018, 7, 499.	0.8	9
36	Abstract 4278: Somatic MAPK pathway mutations are associated with high mutational burden and good survival in head and neck squamous cell carcinoma (HNSCC). , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 5347: Somatic mutation and overexpression of anaplastic lymphoma kinase (ALK) are uncommon events in Asian head and neck cancers. , 2018, , .		0
38	Exome and genome sequencing of nasopharynx cancer identifies NF- κ B pathway activating mutations. Nature Communications, 2017, 8, 14121.	5.8	227
39	An update on genomic-guided therapies for pediatric solid tumors. Future Oncology, 2017, 13, 1345-1358.	1.1	2
40	Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer, 2017, 17, 375.	1.1	125
41	Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer. Oncotarget, 2017, 8, 106486-106498.	0.8	12
42	JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against <i>MYCN</i> -amplified small cell lung cancer. Oncotarget, 2017, 8, 86312-86324.	0.8	37
43	Abstract 646: Targeting MHC class I molecules and immune checkpoints as key immune evasion strategies in EBV-associated nasopharyngeal carcinoma. , 2017, , .		1
44	Abstract 5712: Potential clinical significance of downregulation of MAPK pathway components mRNA expression in head and neck squamous cell carcinoma (HNSCC). , 2017, , .		0
45	The cylindromatosis (CYLD) gene and head and neck tumorigenesis. Cancers of the Head & Neck, 2016, 1, 10.	6.2	23
46	An update of ALK inhibitors in human clinical trials. Future Oncology, 2016, 12, 71-81.	1.1	9
47	Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Molecular Cancer Research, 2016, 14, 278-286.	1.5	48
48	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS ONE, 2016, 11, e0166185.	1.1	4
49	MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget, 2016, 7, 23300-23311.	0.8	8
50	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. PLoS ONE, 2015, 10, e0135750.	1.1	51
51	Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 541-551.	1.8	82
52	miR-466 is putative negative regulator of Coxsackie virus and Adenovirus Receptor. FEBS Letters, 2015, 589, 246-254.	1.3	14
53	TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells. Oncology Letters, 2015, 9, 569-574.	0.8	26
54	JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. Neoplasia, 2015, 17, 256-264.	2.3	59

#	ARTICLE	IF	CITATIONS
55	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 238.	3.4	44
56	Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2015, 126, 169-180.	3.9	156
57	A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy. <i>Current Cancer Drug Targets</i> , 2015, 15, 327-336.	0.8	22
58	<i>Andrographis paniculata</i> elicits anti-invasion activities by suppressing TM4SF3 gene expression and by anoikis-sensitization in esophageal cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 3570-87.	1.4	9
59	Identification of Mutations in the PYRIN-Containing NLR Genes (NLRP) in Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e85619.	1.1	6
60	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1114-1119.	3.3	86
61	Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. <i>Cancer Letters</i> , 2014, 343, 24-32.	3.2	30
62	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection. <i>Molecular Cancer Research</i> , 2014, 12, 571-582.	1.5	94
63	Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. <i>Cancer Letters</i> , 2014, 349, 15-25.	3.2	99
64	Cancers of the lung, head and neck on the rise: perspectives on the genotoxicity of air Pollution. <i>Chinese Journal of Cancer</i> , 2014, 33, 476-80.	4.9	50
65	Abstract 985: The mutational landscape of LN metastasis and recurrence in HNSCC. , 2014, , .		0
66	Abstract 5003: Functional significance of TIGAR expression in nasopharyngeal carcinoma. , 2014, , .		0
67	Targeting tumor hypoxia in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2013, 35, 133-145.	0.9	51
68	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1417-1425.	1.1	12
69	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. <i>Investigational New Drugs</i> , 2013, 31, 567-575.	1.2	38
70	Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. <i>BMC Cancer</i> , 2013, 13, 619.	1.1	76
71	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 602.	1.1	56
72	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. <i>Cancer Discovery</i> , 2013, 3, 761-769.	7.7	505

#	ARTICLE	IF	CITATIONS
73	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. <i>Investigational New Drugs</i> , 2013, 31, 30-38.	1.2	9
74	Full-length Mst1 exhibits growth promoting function in human hepatocellular carcinoma cells. <i>FEBS Letters</i> , 2013, 587, 496-503.	1.3	7
75	The Fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013, 743-744, 78-88.	0.4	50
76	STAT3 as a therapeutic target for Epstein-Barr virus (EBV) associated nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2013, 330, 141-149.	3.2	30
77	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. <i>Clinical Cancer Research</i> , 2013, 19, 380-392.	3.2	90
78	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013, 2013, 1-10.	0.4	20
79	Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer.. , 2013, , .		1
80	Enhanced IL-6/IL-6R Signaling Promotes Growth and Malignant Properties in EBV-Infected Premalignant and Cancerous Nasopharyngeal Epithelial Cells. <i>PLoS ONE</i> , 2013, 8, e62284.	1.1	69
81	Abstract 4668: Antitumor efficacy of AZD1480 in head and neck squamous cell carcinoma.. , 2013, , .		0
82	Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC.. , 2013, , .		0
83	TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression. <i>Cancer Research</i> , 2012, 72, 3270-3281.	0.4	252
84	Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3473-82.	3.3	127
85	Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer. <i>Head and Neck Pathology</i> , 2012, 6, 91-97.	1.3	11
86	Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. <i>Biochemical Pharmacology</i> , 2012, 83, 1146-1158.	2.0	28
87	K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV) associated nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , 2012, 30, 48-58.	1.2	21
88	Abstract 1373: Preclinical activity of axitinib and its associated change of serum biomarkers in nasopharyngeal carcinoma (NPC). , 2012, , .		1
89	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines. <i>Cancer Research</i> , 2012, 72, 4602-4602.	0.4	2
90	Abstract 2811: Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular carcinoma. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
91	Abstract 2037: Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. , 2012, , .		0
92	FHL2 exhibits anti-proliferative and anti-apoptotic activities in liver cancer cells. <i>Cancer Letters</i> , 2011, 304, 97-106.	3.2	29
93	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. <i>Future Oncology</i> , 2011, 7, 1149-1167.	1.1	191
94	Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. <i>Oncogene</i> , 2011, 30, 1127-1134.	2.6	55
95	FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation. <i>Oncogene</i> , 2011, 30, 1518-1530.	2.6	11
96	Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. <i>Investigational New Drugs</i> , 2011, 29, 401-410.	1.2	21
97	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , 2011, 29, 1123-1131.	1.2	28
98	Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , 2011, 29, 1241-1252.	1.2	17
99	Abstract 1006: TP53-induced glycolysis and apoptosis regulator (TIGAR) induces NADPH production and growth in nasopharyngeal carcinoma cells. , 2011, , .		0
100	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010, 28, 107-114.	1.2	56
101	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. <i>Investigational New Drugs</i> , 2010, 28, 413-420.	1.2	58
102	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. <i>Investigational New Drugs</i> , 2010, 28, 326-333.	1.2	40
103	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. <i>Biochemical Pharmacology</i> , 2010, 79, 842-852.	2.0	20
104	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation. <i>Biochemical Pharmacology</i> , 2010, 79, 1772-1780.	2.0	28
105	Induction of laryngeal cancer cell death by Entinostat (hydroxyethyl xanthine derivative) and cisplatin. <i>Head and Neck</i> , 2010, 32, 1506-1518.	0.9	9
106	KIAA0495/PDAM Is Frequently Downregulated in Oligodendroglial Tumors and Its Knockdown by siRNA Induces Cisplatin Resistance in Glioma Cells. <i>Brain Pathology</i> , 2010, 20, 1021-1032.	2.1	40
107	Quantitative Proteomics Analysis Reveals Molecular Networks Regulated by Epidermal Growth Factor Receptor Level in Head and Neck Cancer. <i>Journal of Proteome Research</i> , 2010, 9, 3073-3082.	1.8	26
108	A small molecule inhibitor of NF- κ B, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. <i>Cancer Letters</i> , 2010, 287, 23-32.	3.2	36

#	ARTICLE	IF	CITATIONS
109	Abstract 3088: Mammalian sterile-20 like kinase 1(Mst1) upregulates cyclin D1 to promote hepatocellular carcinoma cell growth. , 2010, , .		0
110	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. <i>Journal of Clinical Oncology</i> , 2009, 27, 1235-1242.	0.8	63
111	Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. <i>Carcinogenesis</i> , 2009, 30, 2085-2094.	1.3	66
112	STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells <i>in vitro</i> . <i>International Journal of Cancer</i> , 2009, 125, 1884-1893.	2.3	67
113	Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting. <i>Clinical Cancer Research</i> , 2008, 14, 7682-7690.	3.2	65
114	Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck. <i>Molecular Pharmacology</i> , 2008, 73, 627-638.	1.0	12
115	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1414-1424.	1.9	73
116	Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1. <i>Molecular Pharmacology</i> , 2007, 71, 1435-1443.	1.0	63
117	STAT3 as a therapeutic target in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 231-241.	1.4	212
118	Hong Kong releases Copyright (Amendment) Bill 2006. <i>Computer Law and Security Review</i> , 2006, 22, 418-420.	1.3	1
119	Phosphorylation of TNF- α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6901-6906.	3.3	130
120	Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells. <i>Neoplasia</i> , 2005, 7, 426-431.	2.3	51
121	Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. <i>Oncogene</i> , 2003, 22, 6183-6193.	2.6	78
122	Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2003, 24, 1705-1712.	1.3	41
123	Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2003, 9, 5028-35.	3.2	30
124	Systemic Administration of Naked DNA Encoding Interleukin 12 for the Treatment of Human Papillomavirus DNA-Positive Tumor. <i>Human Gene Therapy</i> , 2002, 13, 177-185.	1.4	30
125	Gastrin-Releasing Peptide Receptor-Mediated Autocrine Growth in Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Cancer Institute</i> , 2002, 94, 375-383.	3.0	63
126	EGFR-mediated cell cycle regulation. <i>Anticancer Research</i> , 2002, 22, 1-11.	0.5	62

#	ARTICLE	IF	CITATIONS
127	Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. <i>Journal of Gene Medicine</i> , 2001, 3, 384-393.	1.4	34
128	Specific Down-regulation of HER-2/neu Mediated by a Chimeric U6 Hammerhead Ribozyme Results in Growth Inhibition of Human Ovarian Carcinoma. <i>Molecular Therapy</i> , 2001, 3, 169-177.	3.7	28
129	Potential of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. <i>Gene Therapy</i> , 1998, 5, 1462-1471.	2.3	12